Comparison of gel and patch estradiol replacement in Brazil, a tropical country

Maturitas

Volumn 36, Issue 1, 2000, Pages 69-74

  Travassos de Figueiredo Alves, Solange ^a   Amélia Sobreira Gomes, Maria ^a   Clapauch, Ruth ^a  

^a HOSPITAL DA LAGOA   (Brazil)

Author keywords

Climate; Skin reactions; Transdermal estradiol

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE; PROGESTERONE;

ADULT; ARTICLE; BRAZIL; CLINICAL TRIAL; DRUG FORMULATION; DRUG TOLERANCE; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GEL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; SKIN MANIFESTATION; TROPIC CLIMATE;

ADMINISTRATION, CUTANEOUS; BRAZIL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GELS; HUMANS; MENOPAUSE; MIDDLE AGED; TROPICAL CLIMATE;

EID: 0343714826     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00131-6     Document Type: Article

References (26)

1. Lufkin E.G., Ory S.J. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo. Clin. Proc. 69:1994;131-135.
2. Osório M.C., Vitola D., Spritzer P. Uso do gel de estradiol-17 (percutâneo no tratamento substitutivo de pacientes pós menopáusicas hipertensas. Arq. Bras. Endocrinol. Metab. 36:1992;40-43.
3. Crook D. The metabolic consequenses of treating postmenopausal women with non-oral hormone replacement therapy. Br. J. Obstet. Gynaecol. 104(Suppl 16):1997;S4-S13.
4. Padwick M.L., Endacott J., Whitehead M.I. Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am. J. Obstet. Gynecol. 152:1985;1085-1091.
5. The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil 1993;38:5-11.
6. Corson S.L. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. Int. J. Fertil. 38(Suppl 1):1993;S36-S44.
7. Rozenbaum H., Birkhäuser M., De Nooyer C., Lambotte R, Pornel B, Schneider H, Studd J Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. Maturitas. 25:1996;161-173.
8. Gordon S.F. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am. J. Obstet. Gynecol. 173:1995;998-1004.
9. Hirvonen E., Cacciatore B., Wahlström T., Rita H., Wilén-Rosenqvist G. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br. J. Obstet. Gynaecol. 104(Suppl 16):1997;S26-S31.
10. Erianne J.A., Winter L. Jr Comparison of the local tolerability and adhesion of a new matrix system (Menorest®) for estradiol delivery with an established transdermal membrane system (Estraderm-TTS®). Maturitas. 26:1997;95-101.
11. Utian W.H. Clinical experience with transdermal estradiol in the treatment of the climacteric. Minerva. Endocrinol. 14:1989;45-48.
12. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D, Lu K, Eggena P, Hershman J.M., Alkjaersig D., Fletcher A.P., Judd H.L. Biologic effects of transdermal estradiol. New Engl. J. Med. 314:1986;1615-1620.
13. Ellerington M.C., Whitcroft S.I.J., Whitehead M.I. HRT: Developments in therapy. Br. Med. Bull. 48:1992;401-425.
14. Utian W.H. Transdermal estradiol overall safety profile. Am. J. Obstet. Gynecol. 156:1987;1335-1338.
15. Holdiness M.R. A review of contact dermatitis associated with transdermal therapeutic systems. Contact Dermatitis. 20:1989;3-9.
16. McCarthy T., Dramusic V., Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate. Am. J. Obstet. Gynecol. 166:1992;2005-2010.
17. Sentrakul P., Chompootaweep S., Sintupak S., Tasanapradit P., Tunsaringkarn K., Dusitsin N. Adverse skin reactions to transdermal oestradiol in tropical climate. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women. Maturitas. 13:1991;151-154.
18. O'Neill S., Kirkegard Y. An Australian experience of transdermal oestradiol patches in a subtropical climate. Aust. NZ J. Obstet. Gynaecol. 33:1993;327-329.
19. Frenkel Y., Kopernik G., Lazer S., Tugendreich D., Zruica N., Oetlinger M., Tendler R., Jerr D.M. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas. 20:1994;31-36.
20. Hurkmans J.F.G.M., Boddé H.E., Van Driel L.M.J., Van Dorne H., Junginger H.E. Skin irritation caused by transdermal drug delivery systems during long-term (5 days) application. Br. J. Dermatol. 112:1985;461-467.
21. Hirvonen E., Lamberg-Allardt C., Lankinen K.S., Geurts P., Wilén Rosenqvist G. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br. J. Obstet. Gynaecol. 104(Suppl 16):1997;S19-S25.
22. Meireles R.M.R., Pífano D.Q.A., Oliveira S.P., Póvoa L.G., Leite D.B. Reposição hormonal por via transdérmica, níveis séricos de estradiol. Femina. 23:1995;305-307.
23. Scott R.T. Jr, Ross B., Anderson C., Archer D.F. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet. Gynecol. 77:1991;758-764.
24. Reginster J.Y., Sarlet N., Deroisy R., Albert A., Gaspard U., Franchimont P. Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif. Tissue Int. 51:1992;340-343.
25. Vihtamäki T., Tuimala R. Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers? Maturitas. 28:1998;199-203.
26. Wygoda M.M., Filippo R.B. Jr, Gomes M.A.S., Clapauch R. Monitorizando a terapia de reposição estrogênica (TRE) na menopausa. Arq Bras Endocrinol. Metab. 43:1999;336-343.